DC-XYLEM
Manchester City Football Club’s global community program, Cityzens Giving, and global water technology leader, Xylem (NYSE: XYL) are calling on football fans to vote for their top project as the Water Heroes Academy returns for a second year. From November 22 to December 5, fans from around the world can vote for one of five new football and water projects from young leaders working to tackle global water issues in Buenos Aires, Cape Coast, Kuala Lumpur, Melbourne, and Mexico City.
Young leaders involved in this year’s program are using the power of football to provide essential education on water, sanitation, and hygiene in a bid to tackle water challenges specific to their communities. Projects include improving access to safe water in underserved communities in Buenos Aires and Cape Coast, building flood-resilient communities in Mexico City and Kuala Lumpur, and advancing water sustainability education in Melbourne.
The top-voted project will win the opportunity for young leaders to experience a once-in-a-lifetime trip to the Etihad Stadium. There, they will learn more about water challenges and solutions, and receive further training on how they can help improve the health and well-being of young people in their communities. Each of the Water Heroes Academy projects will receive funding, educational tools, training, and mentoring from Xylem and Cityzens Giving, providing young leaders the resources needed to create their own unique programs going forward.
The Water Heroes Academy is a joint initiative by Cityzens Giving and Xylem that aims to positively impact 20,000 young people over the next four years. Last year, the program engaged more than 75 young water leaders and delivered vital education to more than 6,000 young people in São Paulo, Mumbai, Cape Town, New York City, and Shanghai. Mumbai was the winning project, having received thousands of fan votes. Delivered in collaboration with Magic Bus India Foundation, the project aimed to improve local access to safe water, sanitation, and hygiene.
“In my community, many children aren’t able to access clean water in school, which means they fall ill and can no longer attend class due to poor health,” said Varsha, a Young Leader from the Mumbai Team. “The opportunity to better the lives of people in my community through awareness and education motivates me. I’m incredibly proud to contribute to the development of my community and make a positive difference in the lives of young people through my experience with the Water Heroes Academy.”
“We’re thrilled to be working with Xylem to spotlight five more of our inspiring Water Heroes Academy projects around the world, celebrating our Cityzens Giving young leaders who are all making such an important impact in their local communities,” said Tom Pitchon, Global Foundation Director at City Football Group. “It was fantastic to welcome our Mumbai water heroes to Manchester last season, and we look forward to welcoming young leaders from the top-voted project this year, so vote now!”
“We are incredibly proud of our partnership with Manchester City and the global network of young water leaders created through the Water Heroes Academy program,” said Randolf Waters, Senior Director of Global Partnerships & Branding at Xylem. “In spotlighting the work these incredible water leaders are doing locally, we hope to inspire more young people to get involved in tackling water issues and drive positive change on a global level. I encourage football fans to get behind our water heroes and vote for their favorite project.”
To hear the story of each project and to vote for your top project, visit: www.mancity.com/waterheroes
About Xylem
Xylem (XYL) is a leading global water technology company committed to solving critical water and infrastructure challenges with innovation. Our 17,000 diverse employees delivered revenue of $5.2 billion in 2021. We are creating a more sustainable world by enabling our customers to optimize water and resource management and helping communities in more than 150 countries become water secure. Join us at www.xylem.com.
About Manchester City Football Club
Manchester City FC is an English Premier League club initially founded in 1880 as St Mark’s West Gorton. It officially became Manchester City FC in 1894 and has since then gone onto win the European Cup Winners’ Cup, eight League Championship titles, including six Premier League titles (2012, 2014, 2018, 2019, 2021, 2022), and six FA Cups. Manchester City FC is one of 12 clubs comprising the City Football Group and counts New York City FC and Melbourne City FC among its sister clubs.
Under manager Pep Guardiola, one of the most highly-decorated managers in world football, the Club plays its domestic and UEFA Champions League home fixtures at the Etihad Stadium, a spectacular 55,000 seat arena that City have called home since 2003. Today, the Stadium sits on the wider Etihad Campus, which also encompasses the City Football Academy, a state-of-the-art performance training and youth development facility located in the heart of East Manchester. Featuring a 7,000 capacity Academy Stadium, the City Football Academy is also where Manchester City Women’s Football Club and the Elite Development Squad train on a daily basis and play their competitive home games.
For more information, please visit www.mancity.com.
About Cityzens Giving
Cityzens Giving is an award-winning global programme, empowering young leaders to use football as a tool to uplift the health of children and young people in cities around the world. Projects are run by young people for young people, with fans, staff and partners across City Football Group getting involved in diverse ways, from volunteering and fundraising to donating and having a say in how projects are supported. In addition to long-term grant funding, young leaders access training in community football and leadership from our Club community coaches and networking opportunities with other community football projects worldwide. This includes face to face training in country, remote support, and regular global gatherings to facilitate the flow of know-how and learning. Each year, Cityzens Giving supports over 1,000 Young Leaders to positively impact the health of thousands of young people in 25 cities across the globe.
For more information, please visit https://www.mancity.com/community/global-projects.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221122005464/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TreeFrog Therapeutics Announces Changes to Executive Committee With the Arrival of Mark Rothera as Chief Executive Officer & Board Member to Spearhead Next Phase of Growth16.12.2025 09:05:00 CET | Press release
TreeFrog Therapeutics, a French biotech focused on bringing regenerative medicine to millions through their proprietary cell technology, C-Stem™ is delighted to announce the appointment of skilled biotech leader, Mark Rothera, as Chief Executive Officer and Board member. He succeeds Frédéric Desdouits, who is stepping down after five years in the role. In the new leadership configuration, co-founders Kévin Alessandri and Maxime Feyeux will transition from daily operations to focus on their roles on the Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251215145193/en/ Mark Rothera, CEO TreeFrog Therapeutics Elsy Boglioli, Chair of the Board of TreeFrog Therapeutics, commented “On behalf of the Board, we are delighted to welcome Mark to TreeFrog. His 30+ years of biopharma leadership, including most recently, three biotech CEO roles in gene therapy and biologics, will be invaluable as we advance our Parkinson’s and liver
RoslinCT and Ayrmid Ltd. Announce Expansion of Strategic Partnership to Manufacture Omisirge® (omidubicel-onlv) for Second FDA-Approved Indication in Severe Aplastic Anemia (SAA)16.12.2025 09:00:00 CET | Press release
RoslinCT is performing technology transfer and will support commercial manufacture of Omisirge® for an additional indication following successful clinical trialsOmisirge® now FDA-approved for an expanded patient population in hematologyRoslinCT continues to support and advance multiple cell therapy projects at its Hopkinton, MA facility Ayrmid Ltd., the parent company of Gamida Cell Inc., a pioneering cell therapy company transforming cells into powerful therapeutics, and RoslinCT, a global leader in cell and gene therapy contract development and manufacturing, today announced the expansion of their strategic partnership to include the execution of a commercial supply agreement to support production of Omisirge® (omidubicel-onlv). Following positive clinical trial results, Omisirge® has received FDA approval for a second indication, broadening its use in the treatment of hematology patients. Under the commercial supply agreement, RoslinCT will complete technology transfer and support c
Echoworx Secures FSQS-Netherlands Certification, Strengthening Trust in Financial Data Protection16.12.2025 07:00:00 CET | Press release
Leading encryption provider deepens commitment to European financial sector with rigorous new supplier qualification, building on existing UK & Ireland certification. Echoworx, a global leader in email and data encryption, proudly announces it has achieved Financial Services Qualification System (FSQS) registered supplier status for the Netherlands. This certification powerfully demonstrates Echoworx’s commitment to the highest standards of security and compliance. This achievement expands on the company’s existing FSQS certification for the UK and Ireland, secured in 2020. By successfully completing the rigorous qualification for the Netherlands, Echoworx reinforces its alignment with the stringent demands of the European financial market. The FSQS system, managed by Hellios, provides a single, reliable standard for vetting third-party suppliers, streamlining procurement for major banks and financial institutions. Think of FSQS as a high-security passport for technology partners. It p
Nippon Electric Glass to Start World’s First Mass Production of Low-Carbon Pharmaceutical Glass Tubing Using an All-Electric Furnace16.12.2025 03:00:00 CET | Press release
Nippon Electric Glass Co., Ltd. (NEG)(TOKYO:5214), a global leader in specialty glass headquartered in Otsu, Japan, announced it will begin the world’s first mass production of pharmaceutical-grade glass tubing using an all-electric melting furnace. Commercial production is scheduled to start in December 2025 at its subsidiary in Selangor, Malaysia. This breakthrough introduces a new manufacturing model for pharmaceutical packaging. By combining NEG’s proprietary all-electric melting technology with renewable energy, CO2 emissions from glass tubing production can be reduced by up to 90%*1 compared with conventional fossil-fuel combustion furnaces. This positions NEG as a major supplier capable of delivering both high-performance borosilicate glass and a significantly lower carbon footprint, directly addressing global sustainability demands from pharmaceutical companies and regulators. NEG is a leading global supplier of arsenic-free, environmentally friendly borosilicate glass tubing f
Esco Aster Signs Exosome Clinical cGMP Manufacturing Contract With Shine-On Biomedical For A Novel First-In-Class HLA-G Targeting Exosome Drug Delivery Platform16.12.2025 02:00:00 CET | Press release
Esco Aster, a vertically integrated cell and derivatives CRDMO based at JTC LaunchPad Singapore, announced CMC manufacturing support for Shine-On Biomedical’s HLA-G targeted exosome program. Shine-On Biomedical sponsored Esco Aster in 2023 for cGMP services, starting with high-yield exosome development using Esco Aster’s cell line platform. The technical reports of process, analytical, and formulation development, exosome drug loading, GMP engineering runs, and stability studies supported Shine-On’s IND submission. The IND was cleared by the U.S. FDA in Q1 2025. Furthermore, Esco Aster is providing technical services for exploratory exosome loading feasibility studies per Shine-On’s instruction. Shine-On Biomedical is an emerging innovator in exosome-based drug delivery. ShineOn’s proprietary product, SOB100, a HLA-G targeted exosome drug delivery carrier, has passed the U.S. FDA IND review and ongoing Phase I study, making it as a first-in-class–potential HLA-G targeted exosome platfo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom